ArticleFrontiers in medicine2026
Development and internal validation of a CatBoost-SHAP-guided nomogram for significant liver fibrosis in children with chronic hepatitis B.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Significant liver fibrosis can develop in children with chronic hepatitis B (CHB), yet liver biopsy is invasive and unsuitable for repeated assessment. We developed an interpretable, non-invasive prediction model for significant fibrosis in pediatric CHB and evaluated whether baseline risk stratification was associated with subsequent treatment outcomes. Methods: This retrospective study included 232 children with CHB who underwent liver biopsy, with significant fibrosis defined as Scheuer stage S ≥ 2. Patients were randomly assigned to a development cohort (80%) and a held-out test set (20%). A CatBoost model with Bayesian hyperparameter optimization was used to identify the most informative predictors, and these variables were incorporated into a logistic regression nomogram guided by Shapley additive explanations (SHAP). Model performance was evaluated by discrimination, calibration, decision curve analysis, and DeLong testing. Associations between baseline risk groups and longitudinal outcomes were examined using generalized estimating equations adjusted for age and sex and Kaplan-Meier analyses. Results: Significant fibrosis was identified in 96 children (41.4%). Liver stiffness measurement, alanine aminotransferase, and platelet count were retained in the final model. The nomogram achieved an area under the receiver operating characteristic curve (AUC) of 0.828 (95% CI, 0.767-0.889) in the development cohort and 0.782 (95% CI, 0.637-0.927) in the held-out test cohort, with performance comparable to that of the CatBoost model ( Conclusions: An interpretable three-variable prediction model based on CatBoost-guided feature selection accurately identified significant fibrosis in children with CHB while maintaining performance comparable to the machine-learning model. Baseline risk stratification was also associated with subsequent treatment outcomes, although external validation is needed before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.